Business
Novo Nordisk beat analyst expectations for the fourth quarter, but the result was overshadowed by softened expectations for this year.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The world continues to wait with bated breath for a treatment for COVID-19, and Pluristem Therapeutics appears to be on the cusp of providing some hope.
Although the data hasn’t been released yet, analysts are making predictions based on what little they do know.
Rexahn said it notified Merck on April 7 of its decision to discontinue the development of RX-5902 for the treatment of metastatic triple-negative breast cancer.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 9, 2020.
AstraZeneca made an announcement describing its internal and partnering efforts to battle COVID-19, the disease caused by the novel coronavirus SARS-CoV-2.
The capital was raised from existing and new investors, including a broad range of institutional investors comprised of pharmaceutical companies, corporate pensions, financial institutions, endowments and foundations, family offices and funds-of-funds.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
Following a setback with its experimental major depressive disorder drug in December, Sage Therapeutics will initiate a corporate restructuring that includes halving its employee headcount in order to focus its resources on the development of its pipeline.
“We are excited to partner with Roche’s strong research and development team,” said Michael Gilman, Arrakis’ chief executive officer.
The CDC findings were based on an analysis of 2,572 known juvenile cases of COVID-19 that were part of a batch of 149,760 laboratory-confirmed COVID-19 cases.